SDC1 and triple-negative breast carcinoma: Triple-negative breast cancer cell lines with higher CD138 expression, evaluated with fluorescence-activated cell sorting (FACS), were markedly more sensitive to indatuximab ravtansine than triple-negative breast cancer cell lines with two-fold lower CD138 expression.